The Journal for Nurse Practitioners
Volume 8, Issue 1 , Pages 56-60 , January 2012

Hyperphosphatemia: Consequences and Management Strategies

  • Timothy V. Nguyen, PharmD

      Affiliations

    • Timothy V. Nguyen, PharmD, CCP, FASCP, is an assistant professor of pharmacy practice at Arnold & Marie Schwartz College of Pharmacy and Health Sciences at Long Island University (AMSCOP-LIU), an adjunct pharmacology professor at the graduate nursing program at Saint Peter's College, and a clinical pharmacy specialist in nephrology and dialysis at the Mount Sinai Medical Center.
    • ,
  • Amy Wang, PharmD

      Affiliations

    • Amy Wang, PharmD, MBA, BCPS, is an assistant professor of pharmacy practice at the AMSCOP-LIU in Brooklyn and clinical pharmacy specialist in cardiology at New York Methodist Hospital. In compliance with national ethical guidelines, the authors report no relationships with business or industry that would pose a conflict of interest.

References 

  1. Amanzadeh J , Reilly BF . Hypophosphatemia: an evidence-based approach to its clinical consequences and management . Nat Clin Pract Nephrol . 2006;136–148
  2. Coe FL , Favus MJ . Disorders of Bone and Mineral Metabolism . 2nd ed.. Philadelphia: Lippincott Williams & Wilkins; 2002;
  3. Kraft MD , Btaiche IF , Sacks GS , Kudsk KA . Treatment of electrolyte disorders in adult patients in the intensive care unit . Am J Health Syst Pharm . 2005;62:1663–1682
  4. National Kidney Foundation  . K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease . Am J Kidney Dis . 2003;42(4 suppl 3):1–201
  5. Peppers MP , Geheb M , Desai T . Hypophosphatemia and hyperphosphatemia . Crit Care Clin . 1991;7:201–214
  6. Marsell R , Grundberg E , Krajisnik T , et al.   Fibrobast growth factor-23 is associated with PTH and renal function in a population-based cohort of elderly men . Eur J Endocrinol . 2008;158:125–129
  7. Nagano N , Miyata S , Wada M , et al.   Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rates . Kidney Int . 2006;69:531–537
  8. Gutierrez OM , Mannstadt M , Isakova T , et al.   Fibroblast growth factor-23 and mortality among patients undergoing hemodialysis . N Engl J Med . 2008;359:584–592
  9. Tan HL , Liew QY , Loo S , Hawkins R . Severe hyperphosphatemia and associated electrolyte and metabolic derangement following the administration of sodium phosphate for bowel preparation . Anaesthesia . 2002;57:478–483
  10. Dhingra R , Sullivan LM , Fox CS , et al.   Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community . Arch Intern Med . 2007;167:879–885
  11. Voormolen N , Noordzij M , Grootendorst DC , et al.   High plasma phosphate as a risk factor for decline in renal function and mortality in predialysis patients . Nephrol Dial Transplant . 2007;22:2909–2916
  12. Block GA , Hulbert-Shearon TE , Levin NW , et al.   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study . Am J Kidney Dis . 1998;31:607–617
  13. Kestenbaum B , Sampson NJ , Rudser KD , et al.   Serum phosphate levels and mortality risk among people with chronic kidney disease . J Am Soc Nephrol . 2005;16:250–258
  14. Raggi P , Boulay A , Chasan-Taber S , et al.   Cardiac calcification in adult hemodialysis patients. A link between end stage renal disease and cardiovascular disease . J Am Coll Cardiol . 2002;65:695–701
  15. Hutchinson AJ . Oral phosphate binders . Kidney Int . 2009;75:906–914
  16. Renagel (sevelamer hydrochloride, sevelamer carbonate) package insert . Cambridge, MA: Genzyme Corporation; 2007;
  17. European Medicines Agency. Renagel. European Public Assessment Report. EMEA 2009.652342
  18. Schiffl H , Lang SM . Folic acid deficiency modifies the hemapoietic response to recombinant human erythropoietin in maintenance dialysis pts . Nephrol Dial Transplant . 2006;21:133–137
  19. Suki WN , Zabaneh R , Cangiano JL , et al.   Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients . Kidney Int . 2007;72:1130–1137
  20. St Peter WL , Liu J , Weinhandl E , et al.   A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data . Am J Kidney Dis . 2008;51:445–454
  21. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group  . KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) . Kidney Int . 2009;113:S1–130
  22. National Kidney Foundation  . Phosphorus and your CKD diet . http://www.kidney.org/atoz/content/phosphorus.cfm Accessed April 14, 2011.

PII: S1555-4155(11)00256-X

doi: 10.1016/j.nurpra.2011.05.007

The Journal for Nurse Practitioners
Volume 8, Issue 1 , Pages 56-60 , January 2012

Article Tools